A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Pietro Andreoné et al.|New England Journal of Medicine|2016Cited by 1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic AcidGideon M. Hirschfield, Д. А. Шапиро, Andrew L. Mason et al.|Gastroenterology|2014Cited by 563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver DiseaseJuan Pablo Arab, Michael Trauner|Annual Review of Pathology Mechanisms of Disease|2018Cited by 561
Pathophysiological mechanisms of liver injury in COVID‐19Alexander D Nardo, Michael Trauner, Mathias Schneeweiss‐Gleixner et al.|Liver International|2020Cited by 399
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortalityDalila Costa, Thomas Reiberger, Benedikt Simbrunner et al.|Journal of Hepatology|2020Cited by 202